Principal Financial Group Inc. Cuts Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Principal Financial Group Inc. decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 202,017 shares of the company’s stock after selling 16,155 shares during the period. Principal Financial Group Inc. owned about 0.42% of Amphastar Pharmaceuticals worth $9,804,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after purchasing an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares in the last quarter. Asset Management One Co. Ltd. acquired a new position in Amphastar Pharmaceuticals during the third quarter worth $78,000. Mirae Asset Global Investments Co. Ltd. raised its position in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares in the last quarter. Finally, nVerses Capital LLC lifted its holdings in Amphastar Pharmaceuticals by 37.5% in the second quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock valued at $88,000 after acquiring an additional 600 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,533 shares of company stock worth $1,987,482. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ AMPH opened at $36.84 on Tuesday. The firm’s 50-day moving average is $45.02 and its two-hundred day moving average is $44.45. The company has a market capitalization of $1.77 billion, a PE ratio of 12.28, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.